Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma

Kimberly Noonan, RN, MS, CNP, AOCN®; Sandra Rome, RN, MN, AOCN®, CNS; Beth Faiman, PhD, MSN, APRN-BC, AOCN®; Daniel Verina, MSN, RN, ACNP


Background: Venous thromboembolism (VTE) and cardiovascular (CV) disease can occur in patients with multiple myeloma. Although VTE and CV disease are separate medical conditions, they can be serious and even life-threatening.

Objectives: The objectives of this article are to describe risk factors for cancer-associated VTE, describe the influence of CV disease on patients with multiple myeloma, and review the approaches to VTE and CV disease identification and treatment.

Methods: PubMed and CINAHL® databases were used to identify literature to describe VTE and CV in patients diagnosed with multiple myeloma.

Findings: When present in patients with multiple myeloma, VTE and CV disease can limit patient tolerance for myeloma treatment and, therefore, decrease therapeutic options.

View Article @ cjon.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles